501 AZD2796, a myeloid checkpoint inhibitor targeting LILRB2 that promotes pro-inflammatory responses by macrophages and enhances T cell anti-tumor activity

501 AZD2796, a myeloid checkpoint inhibitor targeting LILRB2 that promotes pro-inflammatory responses by macrophages and enhances T cell anti-tumor activity

Bibliographic Details
Main Authors: Simon Dovedi, Mark Cobbold, Georgina Bowyer, Kathy Mulgrew, Fernanda Arnaldez, Des C Jones, Lorraine Irving, Becki Dudley, Marcin Wolny, Seraina Blümli, Ellie Chatzopoulou, Alan Sandercock, Stacy Pryts
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items